• Nine abstracts ready for the SfN conference in November.
  • Joined-up preclinical and clinical trials to advance psilocybin drug development
  • Transpharmation joins HaPpY team to help break the vicious cycle of chronic pain & mood disorders, see News for details
  • Announcing new premises in Poland with a focus on neuropsychiatric disorders...
  • New state-of-the-art premises at Discovery Park, Kent


News you can use

Transpharmation announces the opening of a new laboratory in Poland. “We see Poland rising within the biotechnology and drug-discovery sector, with pharmaceutical companies moving and expanding to develop new technologies and focus on novel treatments to tackle neurodegenerative, neuropsychiatric and neurodevelopmental diseases which affect us all,” reveals Mark Duxon CEO. This news comes not long after Transpharmation revealed the launch of additional laboratory space at Discovery Park, Kent, boosting its growing list of facilities and opening up further opportunities to expand its preclinical services.

Read the full press release here


Start a Conversation

preclinical +44 (0)203 633 2807

clinical trials +353 (0)1896 42 60

clinical research +48 515 244 120

EEG contact@transpharmation.co.uk

Copyright ©2021 Transpharmation Ltd. Website created by Identity Ipswich Web Design